chevron_leftBack
As of 24 April 2025, GH Research PLC has a market cap of $589.27M USD, ranking #10972 globally and #41 in Ireland. It ranks #1069 in the Healthcare sector, and #276 in the Biotechnology industry.
Key Stats
Market Cap
$589.27MUSD
Enterprise Value
$401.68MUSD
EBITDA (TTM)
-$50.18MUSD
Net Income (TTM)
-$38.96MUSD
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Velichka Valcheva
open_in_new
Employees
50
Founded
2018
IPO
25 Jun 2021
Website
ghres.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 1% | 5.2% | -24% | 7.5% | 14% | -19% |
Upcoming Earnings
Earnings Date
Fri, May 2
Earnings Time
sunny
Before Open
EPS Estimate
-$0.2400
Revenue Estimate
-
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
GHRS
ISIN: IE000GID8VI0
Shares Out.:
Shares Outstanding:
62.028M1
Shares Float:
40.443M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
9.50 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About GH Research PLC
GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorder and a current major depressive episode, as well as female patients with postpartum depression. The company also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
